Leerink Partners analyst Jonathan Chang maintained a Hold rating on Genmab (NASDAQ:GMAB) A/S on Wednesday, setting a price target of $37, which is approximately 1.07% below the present share price of $37.4.
Chang expects Genmab A/S to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Genmab, with an average price target of $42.8.
The analysts price targets range from a high of $47 to a low of $37.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.58 billion and a net profit of $532 million. The company's market cap is $24.44 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 25.0% and a 47.14% success rate.
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.